Hales Chadwick M
Department of Neurology, Center for Neurodegenerative Disease, Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, 6 Executive Park Drive, Atlanta, GA 30329, USA.
Med Clin North Am. 2025 Mar;109(2):463-483. doi: 10.1016/j.mcna.2024.10.003. Epub 2024 Nov 19.
Alzheimer's disease (AD) is the most common neurodegenerative disorder, and for providers the term AD is often avoided, favoring generic terms like memory loss or dementia. This is partly not only by limitations in using diagnostics and busy clinics but also by a sense that an AD diagnosis will not lead to a meaningful change in management. However, a turning point has occurred with advancements in diagnostics and disease-modifying therapies. Additionally, AD prevention therapies are not too far into the future. This review will cover AD clinical presentation and symptomatic management with focus on AD diagnostics and disease-modifying therapies.
阿尔茨海默病(AD)是最常见的神经退行性疾病,对于医疗服务提供者来说,他们常常避免使用“AD”这个术语,而更倾向于使用失忆或痴呆等通用术语。部分原因不仅在于诊断方法的局限性和诊所的繁忙,还在于一种观念,即AD诊断不会导致治疗管理上有意义的改变。然而,随着诊断技术和疾病修饰疗法的进步,情况出现了转机。此外,AD预防疗法也为期不远。本综述将涵盖AD的临床表现和症状管理,重点关注AD诊断和疾病修饰疗法。